Liquidity and Capital Resources
As at September 30, 2007, the Company had available cash, cash equivalents and marketable securities of $70,637,000, compared to $48,758,000 at December 31, 2006. The increase is primarily due to proceeds received from the issue of convertible notes in May 2007 and is partially offset by funds used in operating activities.
On May 2, 2007, the Company issued $80,000,000 aggregate principal
amount of convertible notes, consisting of $40,000,000 6% senior
convertible notes due in 2027 and $40,000,000 5% senior subordinated
convertible notes due in 2012. The 6% senior convertible notes have an
initial conversion price equal to the lesser of $12.68 or the 5-day
weighted average trading price of the common shares preceding any
conversion, subject to adjustments in certain circumstances. The Company
will pay interest on the 6% senior convertible notes until maturity on May
2, 2027, subject to earlier repurchase, redemption or conversion. The 5%
senior subordinated convertible notes were subject to mandatory conversion
into common shares under certain circumstances. In connection with this
transaction, the Company issued warrants to purchase an aggregate of
2,250,645 common shares until May 2, 2012, at an initial purchase price of
$12.68 per share, subject to adjustments in certain circumstances. During
the quarter ended June 30, 2007, $10,500,000 of the 6% senior convertible
notes were converted into 1,653,859 common shares and the totality of the
5% senior subordinated convertible notes were converted into 4,444,449
common shares. During the quarter ended September 30, 2007, an additional
$25,000,000 6% senior convertible notes were converted into 3,965,462
common shares. Net proceeds from the offering were $74,279,000 and, as of
Sep
'/>"/>
| SOURCE NEUROCHEM INC. Copyright©2007 PR Newswire. All rights reserved |